A phase II trial of carboplatin plus S-1 for elderly patients with advanced non-small cell lung cancer with wild type EGFR (OLCSG1202).

Akihiro Bessho,Nobuaki Ochi,Shoichi Kuyama,Nobukazu Fujimoto,Takahiro Umeno,Kiichiro Ninomiya,Genyo Ikeda,Daijiro Harada,Daizo Kishino,Shinobu Hosokawa,Kenichi Chikamori,Naoyuki Nogami,Shingo Harita,Hiroshi Ueoka,Katsuyuki Hotta,Nagio Takigawa,Mitsune Tanimoto,Katsuyuki Kiura

A phase II trial of carboplatin plus S-1 for elderly patients with advanced non-small cell lung cancer with wild type EGFR (OLCSG1202).

2017

Akihiro Bessho
Nobuaki Ochi
Shoichi Kuyama
Nobukazu Fujimoto
Takahiro Umeno
Kiichiro Ninomiya
Genyo Ikeda
Daijiro Harada
Daizo Kishino
Shinobu Hosokawa
Kenichi Chikamori
Naoyuki Nogami
Shingo Harita
Hiroshi Ueoka
Katsuyuki Hotta
Nagio Takigawa
Mitsune Tanimoto
Katsuyuki Kiura

e20614Background: S-1 is an oral fluoropyrimidine anticancer agent that combines tegafur, gimeracil, and oteracil potassium. Two phase III trials in advanced non-small cell lung cancer (NSCLC) show...

Keywords:

Carboplatin
Wild type
Lung cancer
Pathology
Cancer research
Medicine
Tegafur
Oncology
Internal medicine
non small cell
OTERACIL POTASSIUM
phase iii trials

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations